Immix Biopharma Inc (IMMX)

$2.19 -0.09 (-3.95%)
Market Cap 63.15M
Revenue (ttm) 0.00
Net Income (ttm) -21.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 175,300
Avg Vol 203,678
Day's Range N/A - N/A
Shares Out 28.83M
Stochastic %K 21%
Beta 0.28
Analysts Strong Sell
Price Target $7.00

Company Profile

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was in...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 651 8041
Address:
11400 West Olympic Boulevard, Suite 200, Los Angeles, United States
ImmxBeliever
ImmxBeliever Aug. 21 at 2:16 PM
$IMMX My recent purchases were timely Cheers
0 · Reply
BetterThanBuffett8
BetterThanBuffett8 Aug. 21 at 10:28 AM
$IMMX https://seekingalpha.com/news/4487027-abbvie-closes-capstan-therapeutics-acquisition
3 · Reply
ImmxBeliever
ImmxBeliever Aug. 20 at 8:56 PM
$IMMX I’m done buying. I’ve got just under 150K shares I’m patient. This will hit by 12/31
0 · Reply
BetterThanBuffett8
BetterThanBuffett8 Aug. 17 at 2:49 AM
$IMMX @ImmxBeliever Are you thinking buyout or will they bring it to market themselves?
4 · Reply
ImmxBeliever
ImmxBeliever Aug. 16 at 6:37 PM
$IMMX another position filled
0 · Reply
ImmxBeliever
ImmxBeliever Aug. 15 at 12:04 AM
$IMMX New job posting
0 · Reply
PMtrader_92
PMtrader_92 Aug. 14 at 5:50 AM
$IMMX so much volume lately
0 · Reply
ImmxBeliever
ImmxBeliever Aug. 14 at 1:37 AM
$IMMX Great interview for all new investors No cash issues until mid 2026 File Bla Q1 Buyout discussed https://youtu.be/_b-4UcAoH9c?si=HsAy7Xg7W7h79Bai
0 · Reply
Dingalingading
Dingalingading Aug. 13 at 9:20 PM
$IMMX undervalued and easy win. surprised the price isn't higher. But it will be...
0 · Reply
Dingalingading
Dingalingading Aug. 13 at 4:17 PM
$IMMX folks are excited!
0 · Reply
Latest News on IMMX
Immix Biopharma Announces Other Serious Diseases Strategy

Aug 6, 2025, 12:30 PM EDT - 17 days ago

Immix Biopharma Announces Other Serious Diseases Strategy

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

Jul 11, 2025, 9:36 AM EDT - 6 weeks ago

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

Jul 7, 2025, 9:35 AM EDT - 6 weeks ago

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

Immix Biopharma Attends FDA CEO Forum in Washington DC

Jun 6, 2025, 9:39 AM EDT - 2 months ago

Immix Biopharma Attends FDA CEO Forum in Washington DC

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Jun 3, 2025, 2:55 PM EDT - 2 months ago

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

May 23, 2025, 9:05 AM EDT - 3 months ago

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

May 22, 2025, 4:02 PM EDT - 3 months ago

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

May 21, 2025, 4:03 PM EDT - 3 months ago

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

Apr 23, 2025, 10:04 AM EDT - 4 months ago

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Feb 10, 2025, 9:35 AM EST - 6 months ago

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

Jan 7, 2025, 9:34 AM EST - 8 months ago

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

Dec 19, 2024, 9:35 AM EST - 8 months ago

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

Dec 16, 2024, 9:48 AM EST - 8 months ago

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

Dec 10, 2024, 9:39 AM EST - 9 months ago

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

Dec 9, 2024, 9:33 AM EST - 9 months ago

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

Nov 25, 2024, 9:32 AM EST - 9 months ago

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Oct 2, 2024, 9:32 AM EDT - 11 months ago

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

Sep 19, 2024, 9:31 AM EDT - 1 year ago

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Aug 28, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

Jul 25, 2024, 9:36 PM EDT - 1 year ago

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Jul 8, 2024, 9:31 AM EDT - 1 year ago

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

Jun 17, 2024, 9:35 AM EDT - 1 year ago

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

May 10, 2024, 9:35 AM EDT - 1 year ago

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

Apr 29, 2024, 9:39 AM EDT - 1 year ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

Immix Biopharma on Track to Dose NXC-201 Patients in United States

Apr 18, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma on Track to Dose NXC-201 Patients in United States

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Apr 15, 2024, 9:36 AM EDT - 1 year ago

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

Mar 20, 2024, 9:46 AM EDT - 1 year ago

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Mar 5, 2024, 9:35 AM EST - 1 year ago

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Immix Biopharma 12 Month Review Progress Update

Feb 21, 2024, 9:31 AM EST - 1 year ago

Immix Biopharma 12 Month Review Progress Update

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Feb 8, 2024, 4:45 PM EST - 1 year ago

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

Feb 7, 2024, 9:37 AM EST - 1 year ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

Feb 5, 2024, 10:30 PM EST - 1 year ago

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

Immix Biopharma Announces Proposed Public Offering of Common Stock

Feb 5, 2024, 3:20 PM EST - 1 year ago

Immix Biopharma Announces Proposed Public Offering of Common Stock

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

Jan 24, 2024, 8:35 AM EST - 1 year ago

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

Dec 18, 2023, 9:39 AM EST - 1 year ago

Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023

Dec 11, 2023, 9:36 AM EST - 1 year ago

Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023

Immix Biopharma: Seeking Catalysts To Propel Out Of Microcap Status

Dec 3, 2023, 2:02 AM EST - 1 year ago

Immix Biopharma: Seeking Catalysts To Propel Out Of Microcap Status

Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit

Nov 30, 2023, 9:46 AM EST - 1 year ago

Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

Nov 22, 2023, 9:19 AM EST - 1 year ago

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

Nov 21, 2023, 9:46 AM EST - 1 year ago

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

Nov 6, 2023, 9:12 AM EST - 1 year ago

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients

Nov 6, 2023, 8:40 AM EST - 1 year ago

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients

Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board

Oct 26, 2023, 8:58 AM EDT - 1 year ago

Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board

Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Oct 16, 2023, 9:05 AM EDT - 2 years ago

Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

Oct 3, 2023, 9:14 AM EDT - 2 years ago

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Oct 2, 2023, 8:06 AM EDT - 2 years ago

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis

Sep 21, 2023, 8:55 AM EDT - 2 years ago

U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis

Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Sep 19, 2023, 9:10 AM EDT - 2 years ago

Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum

Sep 19, 2023, 7:00 AM EDT - 2 years ago

Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum

Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board

Sep 1, 2023, 8:39 AM EDT - 2 years ago

Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board

ImmxBeliever
ImmxBeliever Aug. 21 at 2:16 PM
$IMMX My recent purchases were timely Cheers
0 · Reply
BetterThanBuffett8
BetterThanBuffett8 Aug. 21 at 10:28 AM
$IMMX https://seekingalpha.com/news/4487027-abbvie-closes-capstan-therapeutics-acquisition
3 · Reply
ImmxBeliever
ImmxBeliever Aug. 20 at 8:56 PM
$IMMX I’m done buying. I’ve got just under 150K shares I’m patient. This will hit by 12/31
0 · Reply
BetterThanBuffett8
BetterThanBuffett8 Aug. 17 at 2:49 AM
$IMMX @ImmxBeliever Are you thinking buyout or will they bring it to market themselves?
4 · Reply
ImmxBeliever
ImmxBeliever Aug. 16 at 6:37 PM
$IMMX another position filled
0 · Reply
ImmxBeliever
ImmxBeliever Aug. 15 at 12:04 AM
$IMMX New job posting
0 · Reply
PMtrader_92
PMtrader_92 Aug. 14 at 5:50 AM
$IMMX so much volume lately
0 · Reply
ImmxBeliever
ImmxBeliever Aug. 14 at 1:37 AM
$IMMX Great interview for all new investors No cash issues until mid 2026 File Bla Q1 Buyout discussed https://youtu.be/_b-4UcAoH9c?si=HsAy7Xg7W7h79Bai
0 · Reply
Dingalingading
Dingalingading Aug. 13 at 9:20 PM
$IMMX undervalued and easy win. surprised the price isn't higher. But it will be...
0 · Reply
Dingalingading
Dingalingading Aug. 13 at 4:17 PM
$IMMX folks are excited!
0 · Reply
ImmxBeliever
ImmxBeliever Aug. 13 at 3:53 PM
$IMMX Amazing new interview discussing buyout https://youtu.be/_b-4UcAoH9c?si=ebAk6sctz5tPrp36
1 · Reply
ImmxBeliever
ImmxBeliever Aug. 13 at 3:36 PM
$IMMX here we go
0 · Reply
PMtrader_92
PMtrader_92 Aug. 13 at 3:27 PM
$IMMX
0 · Reply
BetterThanBuffett8
BetterThanBuffett8 Aug. 13 at 3:10 PM
$IMMX It sounds like the CFO has buyout hopium, too...
0 · Reply
ImmxBeliever
ImmxBeliever Aug. 12 at 10:10 PM
$CVM @TwongStocks I’m 100% certain $IMMX is a grand slam I have about 140K shares. This pic is just one account. Loaded up in the $1S Great interview out today https://youtu.be/_b-4UcAoH9c?si=0ptpI_cmNV5uYiiA
0 · Reply
ImmxBeliever
ImmxBeliever Aug. 12 at 10:02 PM
$IMMX Great interview Buyout is coming https://youtu.be/_b-4UcAoH9c?si=0ptpI_cmNV5uYiiA
0 · Reply
ImmxBeliever
ImmxBeliever Aug. 12 at 9:02 PM
$IMMX CFO talks buyout Cheers
1 · Reply
ImmxBeliever
ImmxBeliever Aug. 12 at 8:24 PM
$IMMX New interview out
1 · Reply
Dingalingading
Dingalingading Aug. 11 at 6:39 PM
$IMMX
0 · Reply
PMtrader_92
PMtrader_92 Aug. 11 at 6:29 PM
$IMMX @immxbeliever blocked me of course for questioning them
0 · Reply
BetterThanBuffett8
BetterThanBuffett8 Aug. 11 at 4:31 PM
$IMMX Great opportunity to keep loading the truck. Buyout or no Buyout the value of the pipeline is worth more than $2.40/share...
0 · Reply
PMtrader_92
PMtrader_92 Aug. 11 at 3:21 PM
$IMMX @shortkillermd and @immxbeliever are the same person the first account got banned for spam. Same hopium for years now. Dont invest in a biotech stock on buyout hopium or your gambling. And to address buffets question, I believe they have a strong therapeutic based on data and that’s all I know as of now and also believe they have enough cash to finish and file for fda approval. What happens after that could be a buyout or they can begin generating revenue through the marketing of there therapeutic. But they misleading nature of people like that is toxic and bad for investors
1 · Reply